Research and analysis

Coronavirus (COVID-19) vaccine adverse reactions

A weekly report covering adverse reactions to approved COVID-19 vaccines

Documents

COVID-19 vaccine Pfizer analysis print

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

COVID-19 vaccine AstraZeneca analysis print

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

COVID-19 vaccine brand unspecified analysis print

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

The MHRA has played an active role in responding to the coronavirus pandemic. In relation to COVID-19 vaccines, the MHRA has authorised their supply following a rigorous review of their safety, quality and efficacy. The clinical trials of COVID-19 vaccines have shown them to be effective and acceptably safe; however, as part of its statutory functions, the MHRA is responsible for monitoring these vaccines on an ongoing basis to ensure their benefits continue to outweigh any risks.

This is a requirement for all authorised medicines and vaccines in the UK. This monitoring strategy is continuous, proactive and based on a wide range of information sources, with a dedicated team of scientists reviewing information daily to look for safety issues or unexpected rare events.

This weekly report summarises information received via the Yellow Card scheme and will be published regularly to include other safety investigations carried out by the MHRA under the COVID-19 Vaccine Surveillance Strategy.

This report covers the period 9 December 2020 to 21 April 2021.

Published 5 February 2021
Last updated 29 April 2021 + show all updates
  1. Updated to include new data up to 21 April 2021.

  2. We have uploaded the updated weekly summary of Yellow Card reporting on Coronavirus vaccines' ADRs

  3. Updated to include new data up to 5 April 2021.

  4. Updated to include new data up to 28 March 2021.

  5. Updated to include new data up to 21 March.

  6. Updated to include new data up to 14 March.

  7. Published latest ADR (adverse drug reaction) weekly report and iDAPs, covering the period up to 7 March 2021.

  8. Updated pages and PDF attachments to include data from 9 December 2020 to 28 February 2021.

  9. Published updated report with data to 21 February 2021

  10. Published latest ADR (adverse drug reaction) data, covering the period up to 14 February 2021.

  11. Published latest ADR (adverse drug reaction) data, covering the period up to 7 February 2021.

  12. Published latest ADR (adverse drug reaction) data, covering the period up to 31 January 2021.

  13. First published.